top of page
GLOBAL LIFE SCIENCES DEALMAKERS: 30+ YEARS. 300+ CLIENTS & TRANSACTIONS. BILLIONS IN VALUE.
%20(2).jpg)
Sage Group News
D-PLEX100 from Polypid for Prevention of Surgical Site Infections - Seeking a US Licensing Partner
Our client, PolyPid Ltd. ( PolyPid - Optimized Therapeutics ; NASDAQ:PYPD) has a patented surgical site infection (SSI) prevention...
Sage Group Advises Evecxia on Licensing of EVX-101, a Novel Treatment for Depression and OCD Using Serotonin Synthesis Amplification
Evecxia deploys 5-hydroxytryptophan, 5-HTP, to achieve Serotonin Synthesis Amplification. 5-HTP amplifies brain serotonin and have shown...
The Sage Group: 30 Years of Successful Bioscience Transactions
London and New York, September 1 2024 Â - The Sage Group ( www.sagehealthcare.com ), a leading global advisor in the bioscience sector,...
Coagulant’s CT-001 - An Opportunity To License A Novel Factor VIIa with Orphan Drug Designation for the Treatment of Severe Postpartum Hemorrhage (sPPH)
Our client, Coagulant Therapeutics Corporation (CTC), is developing a novel, patented (4 families due to expire 2041-2043 period)...
Partnering/Licensing Opportunity for Tecarfarin, a Phase 3-Ready Oral Anticoagulant for Patients with Certain Orphan Diseases
Cadrenal Therapeutics ( www.cadrenal.com ; NASDAQ: CVKD) is a public U.S. company focused on advancing the development and...
Opportunity to License/Acquire CMX-2043 For Treatment of Traumatic Brain Injury
Ischemix is a privately-held US company developing a novel cytoprotective drug, CMX-2043, for the treatment of acute moderate-to-severe...
BullFrog AI Partners with the Sage Group to Explore JV Opportunities to Advance its Oncology Assets
BullFrog’s oncology assets have been acquired through exclusive licenses with Johns Hopkins University (JHU) and include a Phase 2 ready...
The Sage Group advised Zhimeng Biopharma on a worldwide license to GSK of CB06-036, a TLR8 Agonist
In December 2022, GSK entered into an exclusive license agreement with biopharma company Zhimeng for CB06-036, a TLR8 agonist. Subject to...
bottom of page